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How responsive is
the patient to the
antiplatelet ther-
apy?.
And how can this
responsiveness be
reliably measured?
It is likely that
truly “personalized”
clopidogrel therapy
will require some
combination of both
genetic and ex vivo
platelet aggregation
testing.DITOR’S PAGE
hienopyridines: Time for Personalized Therapy?
rterial thrombosis is largely mediated by platelet activity. Cardiovascular interventions, by
irtue of the injury they produce and the hardware they leave, set the stage for increased plate-
et activity, promote the deposition of platelets, and produce a prothrombotic milieu. This fact
as been well recognized in interventional cardiovascular medicine since its beginning. Early
n, attempts to control thrombosis with anticoagulant drugs were largely abandoned in favor of
ntiplatelet therapy, and in fact one of the first randomized trials in interventional cardiology
as a comparison of warfarin and aspirin therapy (1). As stenting became the default strategy
or treating arterial thrombosis, the vascular rheology changed in a favorable way enabling less
urbulence and more laminar flow within the vessel, thereby decreasing the incidence of acute
hrombosis, which was seen much more commonly in the era before stents were available. The
ore recent introduction of drug-eluting stents has markedly reduced restenosis but, through
he action of inhibited endothelial healing, has re-emphasized the importance of controlling
rterial thrombosis. Dual antiplatelet therapy has become the standard after bare-metal and
rug-eluting stenting, and guidelines reflect strategies that have been developed on the basis of
vidence generated from the pivotal clinical trials (2). Those recommendations have recently
een modified on the basis of conferences involving professional societies and governmental
gencies. Many recommendations, however, are based on the opinion of experts rather than
lear evidence.
Because the function of platelets in relation to interventional procedures is of such clinical
nterest, we have decided to focus this issue of JACC: Cardiovascular Interventions on a series of
rticles directed at platelets and platelet responsiveness. Thienopyridines, in addition to aspirin,
ave become the standard of care, but many issues remain to be resolved. Some of these are:
ow much thienopyridines should be administered acutely? How early should these agents be
iven before interventions? How long should the agents be continued after drug-eluting stent-
ng? How can we safely interrupt these agents when procedures with a high risk of bleeding
ust be performed? How responsive is the patient to the antiplatelet therapy? And how can
his responsiveness be reliably measured? New drugs are poised to enter the market, and im-
ortant considerations regarding selection of more potent antiplatelet agents must balance ef-
ectiveness with safety, a relationship that might vary considerably, depending on patient char-
cteristics. Patient-specific characteristics effecting clopidogrel response include drug–drug
nteractions, changes in bioavailability, and genetic variability in drug-metabolizing enzymes
nd transporters (3). Several of the articles in this mini-focus issue investigate methods to tai-
or clopidogrel therapy, some for individuals and some for larger populations.
Three articles assess altered clopidogrel dosing strategies as a means to improve outcomes
nd address some of the individual variability in clopidogrel pharmacokinetics (4–6). These
tudies highlight the complexities of this issue. Although the PRINC (Plavix Response in
oronary Intervention) study demonstrated that increasing both the loading and maintenance
oses of clopidogrel was associated with improved platelet responsiveness overall, it seems that
nly those patients with decreased ability to create the active metabolite of clopidogrel
CYP2C19*2 or CYP2C19*4 variant allele carriers) truly benefited (4,5). The focus to date has
een on “one size fits all” dosing for clopidogrel; the articles in this issue underscore the need
o assess the individual patient.
Clopidogrel responsiveness is further clouded by the myriad of available ex vivo platelet ag-regation tests. In this issue of JACC: Cardiovascular Interventions alone, 4 different methods of
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719latelet aggregation testing were used. Although adeno-
ine diphosphate–induced optical aggregation has been
onsidered the gold standard for assessing clopidogrel ef-
ectiveness, it is time consuming and technically difficult.
oint-of-care tests, such as the VerifyNow P2Y12 platelet
unction test (Accumetrics, Inc., San Diego, California),
re being used more frequently both clinically and in re-
earch studies. Ex vivo measures of platelet aggregation
re another means to tailor clopidogrel therapy for an in-
ividual patient. It is unclear which of these tests best
redicts clopidogrel responsiveness.
It is likely that truly “personalized” clopidogrel therapy
ill require some combination of both genetic and ex vivo
latelet aggregation testing. Although preliminary results
or both of these modalities are promising, their role in
ractice still remains unclear.
Just as we are beginning to understand the role of indi-
idual patient variability in clopidogrel response, physi-
ians will also soon be confronted with the question of
hich thienopyridine to use. Prasugrel data were pre-
ented to the Food and Drug Administration in Septem-
er 2008, and although the need for further review of the
ata resulted in no action being taken, there might be a
hoice of agent in the near future. Prasugrel is metabo-
ized in a more direct path, has a quicker onset of action,
nd is more potent than the current clopidogrel dosing.
ow will interventionalists use this agent, which might
lso have a greater bleeding risk? Some physicians in Eu-
ope are using the more potent agent acutely and shifting
o clopidogrel for long-term administration. The data to
rive the decisions are largely lacking except for concern
or bleeding risk in patients who have had a prior cere-
rovascular accident, are elderly, or are of small body size.
Cangrelor, an injectable thienopyridine with reversible
latelet binding, is a very short half-life agent that might
rovide opportunities for very prompt antiplatelet activity
nd be useful as a bridge in patients who need to inter-
upt their therapy, because its effect will dissipate within a
ery short time.Further investigation into many of the unresolved issues
egarding protection of our patients from thrombosis after
tent placement will undoubtedly be forthcoming. At the
urrent time physicians caring for these patients have
any questions, and guidelines are incomplete in their
ecommendations. Hopefully new evidence will be forth-
oming in the near future to inform those guidelines so
hat patient care can be optimized. We look forward to
ublishing many of those pivotal investigations in this
ournal.
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